Tags

Type your tag names separated by a space and hit enter

Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet.

Abstract

Obesity is associated with elevated levels of inflammation and metabolic abnormalities which are linked to CVD. The aim of the present study was to investigate whether long-chain n-3 PUFA (LCn-3PUFA), combined with a very-low-energy diet (VLED), facilitated weight loss and weight maintenance, and improvements in blood lipids and inflammatory mediators. This was a double-blind, randomised, controlled trial with two parallel groups. For 14 weeks, one group consumed 6 × 1 g capsules/d of monounsaturated oil (placebo group, PB), and the other group consumed 6 × 1 g capsules/d of LCn-3PUFA (fish oil group, FO), each comprising 70 mg EPA and 270 mg DHA. Both groups were on VLED for 4 weeks (n 14 PB, n 18 FO), which was then followed by 10 weeks of weight maintenance (n 12 PB, n 17 FO). Fasting blood samples, anthropometric measurements and 3 d food diaries were collected at baseline, at 4 and 14 weeks. A greater-than-2-fold increase occurred in plasma levels of EPA and DHA in the FO group (P < 0·001). At 4 weeks, the mean weight loss was -6·54 (SD 2·08) kg (-6·9%) for PB and -6·87 (SD 1·83) kg (-7·7%) for FO. At week 14, after the maintenance phase, there was a further mean decrease in weight, -1·57 (SD 3·7) kg (1·85%) for PB and -1·69 (SD 2·32) kg (-1·9%) for FO. Both groups experienced improved metabolic profiles and there was a significant reduction in fat mass for the FO group at week 14 but not for PB. However, it would appear that supplementation with LCn-3PUFA had no significant effect on weight loss or weight maintenance over the 14 weeks.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, 305C Medical Sciences Building, The University of Newcastle, Callaghan, NSW 2308, Australia.

    Source

    The British journal of nutrition 108:8 2012 Oct 28 pg 1466-74

    MeSH

    Adipose Tissue
    Adult
    Caloric Restriction
    Diet, Reducing
    Dietary Fats
    Dietary Supplements
    Docosahexaenoic Acids
    Double-Blind Method
    Eicosapentaenoic Acid
    Fatty Acids, Omega-3
    Female
    Humans
    Male
    Middle Aged
    Obesity
    Weight Loss

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    22214842

    Citation

    Munro, Irene A., and Manohar L. Garg. "Dietary Supplementation With N-3 PUFA Does Not Promote Weight Loss when Combined With a Very-low-energy Diet." The British Journal of Nutrition, vol. 108, no. 8, 2012, pp. 1466-74.
    Munro IA, Garg ML. Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. Br J Nutr. 2012;108(8):1466-74.
    Munro, I. A., & Garg, M. L. (2012). Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. The British Journal of Nutrition, 108(8), pp. 1466-74. doi:10.1017/S0007114511006817.
    Munro IA, Garg ML. Dietary Supplementation With N-3 PUFA Does Not Promote Weight Loss when Combined With a Very-low-energy Diet. Br J Nutr. 2012 Oct 28;108(8):1466-74. PubMed PMID: 22214842.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. AU - Munro,Irene A, AU - Garg,Manohar L, Y1 - 2012/01/03/ PY - 2012/1/5/entrez PY - 2012/1/5/pubmed PY - 2012/12/27/medline SP - 1466 EP - 74 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 108 IS - 8 N2 - Obesity is associated with elevated levels of inflammation and metabolic abnormalities which are linked to CVD. The aim of the present study was to investigate whether long-chain n-3 PUFA (LCn-3PUFA), combined with a very-low-energy diet (VLED), facilitated weight loss and weight maintenance, and improvements in blood lipids and inflammatory mediators. This was a double-blind, randomised, controlled trial with two parallel groups. For 14 weeks, one group consumed 6 × 1 g capsules/d of monounsaturated oil (placebo group, PB), and the other group consumed 6 × 1 g capsules/d of LCn-3PUFA (fish oil group, FO), each comprising 70 mg EPA and 270 mg DHA. Both groups were on VLED for 4 weeks (n 14 PB, n 18 FO), which was then followed by 10 weeks of weight maintenance (n 12 PB, n 17 FO). Fasting blood samples, anthropometric measurements and 3 d food diaries were collected at baseline, at 4 and 14 weeks. A greater-than-2-fold increase occurred in plasma levels of EPA and DHA in the FO group (P < 0·001). At 4 weeks, the mean weight loss was -6·54 (SD 2·08) kg (-6·9%) for PB and -6·87 (SD 1·83) kg (-7·7%) for FO. At week 14, after the maintenance phase, there was a further mean decrease in weight, -1·57 (SD 3·7) kg (1·85%) for PB and -1·69 (SD 2·32) kg (-1·9%) for FO. Both groups experienced improved metabolic profiles and there was a significant reduction in fat mass for the FO group at week 14 but not for PB. However, it would appear that supplementation with LCn-3PUFA had no significant effect on weight loss or weight maintenance over the 14 weeks. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/22214842/Dietary_supplementation_with_n_3_PUFA_does_not_promote_weight_loss_when_combined_with_a_very_low_energy_diet_ L2 - https://www.cambridge.org/core/product/identifier/S0007114511006817/type/journal_article DB - PRIME DP - Unbound Medicine ER -